血浆血管性血友病因子裂解酶在肝脏疾病发病机制和诊断中的作用

许姗姗; 陈亚利; 张晶

doi:10.3969/j.issn.1001-5256.2016.02.043

血浆血管性血友病因子裂解酶在肝脏疾病发病机制和诊断中的作用

DOI: 10.3969/j.issn.1001-5256.2016.02.043

首都医科大学附属北京佑安医院

基金项目:

北京市教育委员会科技计划面上项目(KM201310025008)；北京市属高等学校高层次人才引进与培养计划项目(CIT&TCD201304178)；

详细信息

中图分类号: R575
计量
- 文章访问数: 2306
- HTML全文浏览量: 14
- PDF下载量: 389
- 被引次数: 0
出版历程
- 收稿日期: 2015-06-18
- 出版日期: 2016-02-20

Role of ADAMTS13 in diagnosis and pathogenesis of liver diseases

Beijing You'an Hospital,Capital Medical University

Research funding:

摘要

摘要: 近期研究表明机体凝血功能和肝脏微循环障碍在肝脏疾病的发生、发展过程中起着重要作用。ADAMTS13又称血管性血友病因子裂解酶,是由肝星状细胞产生的金属蛋白酶,主要功能是裂解血管内皮细胞产生的血管性血友病因子多聚体,从而调节血小板粘附能力,进而影响机体的凝血功能和微循环。回顾ADAMTS13在多种重症肝病如肝硬化、重症酒精性肝炎、干细胞移植后肝静脉阻塞病和移植肝功能障碍等病理生理过程中发挥的重要作用,阐述了其与肝脏疾病严重程度的关系,认为血浆ADAMTS13参与了多种肝脏疾病的发生、发展过程,通过检测其水平和活性有助于肝脏疾病的诊断及鉴别诊断。
- 肝疾病 /
- von Willebrand因子 /
- 金属蛋白酶类 /
- 综述
Abstract: Recent studies have demonstrated that coagulation function and liver microcirculation disturbance are important in the development and progression of liver diseases. ADAMTS13,also known as von Willebrand factor- cleaving protease,is a metalloproteinase produced by hepatic stellate cells,with major functions to cleave the von Willebrand factor multimers produced by vascular endothelial cells,regulate the adhesive capacity of platelets,and influence the body' s coagulation function and microcirculation. The important role of ADAMTS13 in the pathophysiological processes of various severe liver diseases such as liver cirrhosis,severe alcoholic hepatitis,hepatic veno-occlusive disease after stem cell transplantation,and liver graft dysfunction is reviewed in this paper,and its association with the severity of liver diseases is clarified. Plasma ADAMTS13 is involved in the development and progression of various liver diseases,and measurement of its level and activity can help the diagnosis and differential diagnosis of liver diseases.
- liver diseases /
- von Willebrand factor /
- metalloproteases /
- review

HTML全文

参考文献(21)

[1]LANCELLOTTI S,BASSO M,de CRISTOFARO R.Proteolytic processing of von Willebrand factor by adamts13 and leukocyte proteases[J].Mediterr J Hematol Infect Dis,2013,5(1):e2013058.

[2]ZHENG XL.Structure-function and regulation of ADAMTS-13protease[J].J Thromb Haemost,2013,11(Suppl 1):11-23.

[3]de GROOT R,LANE DA,CRAWLEY JT.The role of the ADAMTS13 cysteine-rich domain in VWF binding and proteolysis[J].Blood,2015,125(12):1968-1975.

[4]QU L,JIANG M,QIU W,et al.Assessment of the diagnostic value of plasma levels,activities,and their ratios of von Willebrand factor and ADAMTS13 in patients with cerebral infarction[J].Clin Appl Thromb Hemost,2015.[Epub ahead of print]

[5]UEMURA M,FUJIMURA Y,MATSUMOTO M,et al.Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis[J].Thromb Haemost,2008,99(6):1019-1029.

[6]LISMAN T,BONGERS TN,ADELMEIJER J,et al.Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity[J].Hepatology,2006,44(1):53-61.

[7]KIM W,KIM DJ.Severe alcoholic hepatitis-current concepts,diagnosis and treatment options[J].World J Hepatol,2014,6(10):688-695.

[8]UEMURA M,MATSUYAMA T,ISHIKAWA M,et al.Decreased activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis[J].Alcohol Clin Exp Res,2005,29(12 Suppl):264s-271s.

[9]MATSUYAMA T,UEMURA M,ISHIKAWA M,et al.Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis[J].Alcohol Clin Exp Res,2007,31(1 Suppl):s27-s35.

[10]ISHIKAWA M,UEMURA M,MATSUYAMA T,et al.Potential role of enhanced cytokinemia and plasma inhibitor on the decreased activity of plasma ADAMTS13 in patients with alcoholic hepatitis:relationship to endotoxemia[J].Alcohol Clin Exp Res,2010,34(Suppl 1):s25-s33.

[11]UEMURA M,FUJIMURA Y,KO S,et al.Determination of ADAMTS13 and its clinical significance for ADAMTS13 supplementation therapy to improve the survival of patients with decompensated liver cirrhosis[J].Int J Hepatol,2011,2011:759047.

[12]CAO WJ,NIIYA M,ZHENG XW,et al.Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells[J].J Thromb Haemost,2008,6(7):1233-1235.

[13]BOCKMEYER CL,CLAUS RA,BUDDE U,et al.Inflammationassociated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor[J].Haematologica,2008,93(1):137-140.

[14]CHEUK DK.Hepatic veno-occlusive disease after hematopoietic stem cell transplantation:prophylaxis and treatment controversies[J].World J Transplant,2012,2(2):27-34.

[15]PARK YD,YOSHIOKA A,KAWA K,et al.Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation[J].Bone Marrow Transplant,2002,29(9):789-794.

[16]MATSUMOTO M,KAWA K,UEMURA M,et al.Prophylactic fresh frozen plasma may prevent development of hepatic VOD after stem cell transplantation via ADAMTS13-mediated restoration of von Willebrand factor plasma levels[J].Bone Marrow Transplant,2007,40(3):251-259.

[17]NWABA A,MacQ UILLAN G,ADAMS LA,et al.Tacrolimus-induced thrombotic microangiopathy in orthotopic liver transplant patients:case series of four patients[J].Intern Med J,2013,43(3):328-333.

[18]TAKAHASHI N,WADA H,USUI M,et al.Behavior of ADAMTS13 and von Willebrand factor levels in patients after living donor liver transplantation[J].Thromb Res,2013,131(3):225-229.

[19]NAKAZAWA Y,HASHIKURA Y,URATA K,et al.Von Willebrand factor-cleaving protease activity in thrombotic microangiopathy after living donor liver transplantation:a case report[J].Liver Transpl,2003,9(12):1328-1333.

[20]KATO S,MATSUMOTO M,MATSUYAMA T,et al.Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity[J].Transfusion,2006,46(8):1444-1452.

[21]PEREBOOM IT,ADELMEIJER J,van LEEUWEN Y,et al.Development of a severe von Willebrand factor/ADAMTS13 dysbalance during orthotopic liver transplantation[J].Am J Transplant,2009,9(5):1189-1196.

施引文献

资源附件(0)

访问统计